Predicted to enable signaling receptor activity. Predicted to act upstream of or within positive regulation of synapse assembly. Predicted to be located in membrane. Predicted to be active in plasma membrane. Orthologous to human LRRN1 (leucine rich repeat neuronal 1); INTERACTS WITH 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran.
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased more ...
[S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LRRN1 mRNA; [S-(1,2-dichlorovinyl)cysteine more ...
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with monobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-isobutyl more ...
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with monobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-isobutyl more ...
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with monobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-isobutyl more ...
[S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LRRN1 mRNA; [S-(1,2-dichlorovinyl)cysteine more ...
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased more ...
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased more ...